Agentix Corp.
Agentix Corp.
Your view on AGTX
Overview
What the company does, where it operates, and who runs it.
About Agentix Corp.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Riazul Huda
- Headquarters
- 32932 Pacific Coast Highway, Dana Point, CA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Riazul Huda
- Headquarters
- 32932 Pacific Coast Highway, Dana Point, CA, US
Agentix Corp., a clinical development stage company, focuses on the development and commercialization of therapeutics to treat metabolic diseases. Its product pipeline includes AGTX-2004, a peripherally-acting CB1 receptor antagonist that has demonstrated efficacy in animal models of obesity and type 2 diabetes mellitus; and AGTX-2003, a peripherally-acting CB1 receptor inverse agonist, which has demonstrated efficacy in animal models of obesity and non-alcoholic fatty liver diseases. The company was formerly known as FairWind Energy, Inc. and changed its name to Agentix Corp. in June 2019. Agentix Corp. was incorporated in 2013 and is based in Dana Point, California.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks the stock is worth vs. the current price.
FRC's fair value estimate for Agentix Corp., and the rating behind it. AGTX last traded at $0.05; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Agentix Corp.. Starting points for Agentix Corp.: EPS -$0.01, beta 0.81 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Agentix Corp.. Agentix Corp. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Agentix Corp.. Trailing twelve-month EPS for Agentix Corp. stands at -$0.01. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Agentix Corp.. Agentix Corp. has reported as a listed company since 2015. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Agentix Corp. valued side by side against its closest peers. Agentix Corp. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
Which funds and firms own the stock.
Which institutions hold Agentix Corp., and how their positions are changing. At a $1.9M market value, institutional positions materially move Agentix Corp.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
Buying and selling by Agentix Corp. executives and directors. Shares of Agentix Corp. have traded between $0.02 and $0.10 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Agentix Corp.. Agentix Corp. is a $1.9M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Agentix Corp.. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Agentix Corp.. Coverage tracks Agentix Corp. within Biotechnology (Healthcare). Press releases and market coverage, newest first.